ReviewDrugs2000
Neuroblastoma: current drug therapy recommendations as part of the total treatment approach.
Review in Drugs, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03042429 (Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-risk Neuroblastoma), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-risk Neuroblastoma
Who cites it
22 citing papers in PubMed.
- Stage 4 neuroblastoma: sequential hemi-body irradiation or high-dose chemotherapy plus autologous haemopoietic stem cell transplantation to consolidate primary treatment.British journal of cancer · 2005Trial
- Isolation and transplantation of highly purified autologous peripheral CD34(+) progenitor cells: purging efficacy, hematopoietic reconstitution and long-term outcome in children with high-risk neuroblastoma.Bone marrow transplantation · 2002Trial
- 3D surgical planning of pediatric tumors: a review.International journal of computer assisted radiology and surgery · 2022Review
- Pediatric high risk neuroblastoma with autologous stem cell transplant - 20 years of experience.International journal of pediatrics & adolescent medicine · 2021Article
- Article
- Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979-2015.Paediatric drugs · 2017Article
- RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma.Pharmaceutical research · 2017Review
- Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2015Article
- LIMK2 mediates resistance to chemotherapeutic drugs in neuroblastoma cells through regulation of drug-induced cell cycle arrest.PloS one · 2013Article
- Molecular interaction of Survivin and Piperine by computational docking analyses for neuroblastoma targeting.Annals of neurosciences · 2011Article
- Targeting p53-null neuroblastomas through RLIP76.Cancer prevention research (Philadelphia, Pa.) · 2011Article
- HsMAD2 mRNA expression may be a predictor of sensitivity to paclitaxel and survival in neuroblastoma.Pediatric surgery international · 2011Article
- Detection of human tumor cells by amplicon fusion site polymerase chain reaction (AFS-PCR).The Journal of clinical investigation · 2011Article
- INSM1 promoter-driven adenoviral herpes simplex virus thymidine kinase cancer gene therapy for the treatment of primitive neuroectodermal tumors.Human gene therapy · 2009Article
- New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence.Pharmacology & therapeutics · 2009Review
- 1 alpha-Hydroxyvitamin D2 inhibits growth of human neuroblastoma.Journal of neuro-oncology · 2007Article
- MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening.British journal of cancer · 2006Article
- Diagnostic identification of malignant cells in the cerebrospinal fluid by tumor-specific qRT-PCR.Clinical & experimental metastasis · 2006Article
- [Neuroblastoma].Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2005Review
- Complete surgical resection plus chemotherapy prolongs survival in children with stage 4 neuroblastoma.Pediatric surgery international · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma represents one of the most challenging malignancies for treatment decisions because of its unusual biological behaviour. The features include spontaneous regression (regressive type), maturation to ganglioneuroma (maturative type) and largely treatment-resistant progression (progressive type). Current knowledge allows only partial prediction of type. For practical reasons, patients may be categorised as an 'observation', a 'standard risk' or a 'high risk' treatment arm. During the last 2 decades, 5-year survival rates for children with neuroblastoma have increased from 48 to 67%. The main achievements were the reduction of chemotherapy in patients with localised disease and the increased efficacy of chemotherapy in metastatic neuroblastoma stage 4 (5-year survival increased from 8 to 33%). Different goals for chemotherapy (e.g. stopping rapid progression, improvement of symptoms, induction and maintenance of remission) require different dosages and durations of treatment (range 1 week to 9 months). The main risks of chemotherapy are toxic death (rate up to 15%) predominantly during the periods of bone marrow depression and the development of secondary leukaemias (up to 7% cumulative risk after 4 years). In conclusion, the use of cytotoxic drugs can be completely omitted in a substantial proportion of low risk patients with neuroblastoma. On the other hand, for high risk patients with the disease, intensive polychemotherapy represents the basis and the backbone of treatment among other modalities.
Indexed as
Identifiers
10882162What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.